The DHODH inhibitor IMU-838/Vidofludimus calcium shows a superior compound profile as compared to the approved DHODH inhibitor Teriflunomide/Aubagio

Kohlhof, H; Groeppel, M; Muehler, A; Vitt, D

MULTIPLE SCLEROSIS JOURNAL, 2019; 25 (): 308

Abstract

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索